NeoTYPE® Precision Profile for Solid Tumors

The NeoTYPE Precision Profile analyzes 83 biomarkers through a combination of next-generation sequencing (NGS) and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions. If Pan-TRK IHC is expressed or equivocal, reflex to either NTRK NGS Fusion Panel (Default) or NTRK 1-3 FISH Panel will be added. A microsatellite instability (MSI) NGS result of “indeterminate” will create a reflex to MSI by PCR as long as the tumor percentage is ≥20% for colorectal specimens or ≥40% with paired normal tissue available for non-colorectal specimens.

• NGS (79 genes + 2 biomarkers): AKT1, ALK, APC, ARAF, ATM, ATR, BARD1, BRAF, BRCA1, BRCA2, BRIP1, CDH1, CDK12, CDKN2A, CHEK1, CHEK2, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, ESR1, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL, FBXW7, FGFR1, FGFR2, FGFR3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, KDR, KIT, KRAS (includes G12C mutation), MAP2K1, MET, Microsatellite Instability (MSI), MLH1, MSH2, MSH6, MRE11A (MRE11), MTOR, NBN, NF1, NOTCH1, NRAS, PALB2, PDGFRA, PIK3CA, PMS2, PTCH1, PTEN, PTPN11, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TSC1, TSC2, TERT Promoter, TP53, Tumor Mutation Burden (TMB), VHL

• IHC (2 biomarkers): PD-L1 LDT, Pan-TRK (tech-only available for PD-L1)